This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Bausch & Lomb 'Success' Less Than Meets the Eye

NEW YORK (TheStreet) --Warburg Pincus is opening eyes for all the wrong reasons after agreeing to sell Bausch & Lomb to Valeant Pharmaceuticals (VRX ) for $8.7 billion, in a deal that may net the private equity firm a threefold return on its 2007 buyout investment.

Bausch & Lomb's takeover came near the peak of a leveraged buyout boom in May 2007. However, the deal is now being heralded as a classic investment success given Warburg Pincus's threefold gain, or annual internal rates of return of about 20%, in line with private equity industry standards.

If Bausch & Lomb is typical of how private equity firms generate their oft-celebrated investment returns the deal should be viewed as an indictment of the industry.

Buyout firms are often heralded for two-and-three-bagger investments in superficial analysis, but a closer look at the numbers indicates returns are often generated by a unique arbitrage available only to buyout funds who can raise $1 billion loan with a phone call.

Consider that while Warburg Pincus may be tripling its investment on Bausch & Lomb, the company's value has only increased about $830 million, according to terms of its $3.67 billion May 16, 2007 takeover and Monday's sale to Valeant, which will pay Warburg Pincus $4.5 billion for control of the eye care specialist.

Using just the equity value of Bausch & Lomb, Warburg Pincus's over six year investment in the company has yielded about a 22% absolute gain and annual returns of under 4%. While the growth in Bausch & Lomb's equity value slightly exceeds sub 20% gains posted by the S&P 500 over the span of Warburg Pincus's investment, it isn't worthy of a firm that closed a new $11.2 billion buyout fund earlier in May.

So if Bausch & Lomb was taken private by Warburg Pincus for $3.67 billion and is being sold to Valeant Pharmaceuticals for $4.5 billion, how is the PE firm getting it's much hyped three-bagger?

The simple answer is debt, which, gives Monday's deal it's reported $8.7 billion price tag.

A skeptical view of Monday's deal shows the vast majority of Warburg Pincus's investment gains are a result of Valeant Pharmaceuticals giving the private equity firm cash for its takeover financing.

In taking Bausch & Lomb private, Warburg Pincus appears to have to put up just over $1 billion in cash for control of the company, while financing a remaining $2.59 billion, according to Bloomberg data. In 2012, Bausch & Lomb also took $800 million in additional debt to pay a special dividend to Warburg Pincus and co-investor Welsh Carson.

Happily for Warburg Pincus, it is getting paid in cash for debt the PE firm will effectively throw onto Bausch & Lomb's next owner, Valeant Pharmaceuticals.

According to the terms of Monday's deal, Valeant will repay $4.2 billion in Bausch & Lomb's debt through a mixture of an up-to-$2 billion equity raise and nearly $7 billion in new financing, arranged by Goldman Sachs.

Warburg Pincus may deserve some credit for growing earnings before interest, taxes, depreciation and amortization (EBITDA) and operating cash flow at Bausch & Lomb, but numbers clearly show majority of its investment gains come from taking cash for debt financing.

For instance, Bausch & Lomb was a profitable company when it was acquired by Warburg Pincus. However, the company's interest costs now consume over 100% of its operating income, according to 2010, 2011 and 2012 financial statements in a S-1 filing with the Securities and Exchange Commission.

Employment at Bausch & Lomb has fallen by over 15% during the company's time in private hands. The bulk of an impressive-sounding 33% EBITDA growth between 2011 and 2012, meanwhile, is mostly attributable to escalating interest expense and a tax rate that fell by over 60%.

Judging by financial statements, Bausch & Lomb does generate more revenue, and free cash flow than it did prior to its 2007 buyout. That's why the company's equity value has grown slightly and Bausch & Lomb managed to attract some interest both as an IPO and M&A candidate.

Stock quotes in this article: VRX, GS, HCA, APO, KKR, I 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs